Vaccines and Related Biological Products Advisory Committee
March 6, 2002 Meeting
Date and Time:
The meeting will be held by teleconference on March 6, 2002, 12:30 to 4:30 p.m.
Location:
Food and Drug Administration, Bldg. 29, Conference Room 121, 8800 Rockville Pike, Bethesda, MD. This meeting will be held by a telephone conference call. A speaker telephone will be provided in the conference room to allow public participation in the meeting.
Contact Person:
Jody G. Sachs, D.P.M. or Denise H. Royster, 301-827-0314, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12391. Please call the Information Line for up-to-date information on this meeting.
FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please notify the contact person listed above at least 7 days in advance of the meeting. Persons attending FDA advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.
Agenda:
The committee will complete recommendations pertaining to the influenza virus vaccine formulation for the 2002-2003 season, and review and discuss the research programs of two CBER Laboratories: Laboratories of Hepatitis Virus (LHV) and Laboratory of Vector-borne Viral Diseases (LVVD).
Oral Presentations:
Between approximately 2:00 to 2:30 p.m., and 3:00 to 3:30 p.m. oral presentations from the public will be scheduled. Those desiring to make formal oral presentations should notify the contact person before February 25, 2002.
Closed Committee Deliberations:
From 3:30 to 4:30 p.m., the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy ( 5 U.S.C. 552b(c)(6)).
|
